1. At a Glance (50 words)
3B BlackBio Dx (formerly Kilpest India) is acquiring 100% of Belgium’s Coris Holding SRL for £2.765M (cash + earnout). Coris specializes in antimicrobial resistance (AMR) diagnostics with €5.2M revenue. This cross-border move adds rapid test tech and European presence to 3B’s portfolio. Investors smell a global play.
2. Intro – Why This Matters
From Bhopal to Belgium, 3B just leveled up. Coris is a European pioneer in AMR rapid tests and lateral flow assays. This acquisition means access to global markets, R&D synergies, and expansion beyond PCR. For 3B, it’s not just buying a company—it’s buying a seat at the global diagnostics table.
3. Deep Dive – What’s the Deal?
- Target: Coris Holding SRL, parent of Coris Bioconcept SRL (Belgium).
- Value: £2.15M upfront + £0.615M earnout = £2.765M.
- Structure: 3B (70%) + TRUPCR® Europe (30%) stake acquisition.
- Completion: By 10 Sept 2025.
- Business: AMR rapid tests, respiratory, gastro, and blood-borne diagnostics.
- Scale: FY24 revenue €5.22M, gross margin 58.7%.
4. Strategic Impact – What Changes Now?
- Global Footprint: Belgium facility adds EU presence and distribution.
- Portfolio Expansion: Rapid tests complement 3B’s PCR-based kits.
- Synergy: Shared R&D, manufacturing, and distribution networks.
- Market: Access to 60+ countries via Coris network; AMR segment is red hot.
5. Risks & What to Watch
- EBITDA Negative: Coris FY24 EBITDA –€0.215M; turnaround needed.
- Integration: Aligning teams and products across geographies is no cakewalk.
- Regulatory: EU compliance is complex.
- Execution: Synergy benefits must materialize quickly to justify valuation.
6. Edu Take™ – Final POV
3B’s acquisition of Coris is bold, strategic, and globally relevant. Yes, the Belgian unit is loss-making, but the AMR pipeline and EU distribution network could be game-changers.
Edu Verdict: “Smart buy – provided 3B stitches the Belgian patch without tearing margins.”
Written by EduInvesting Team | 28 July 2025
Tags: 3B BlackBio Dx, Kilpest India, Coris Bioconcept, AMR Diagnostics, Global Acquisition, Edu Style Article, SEBI Regulation 30
